MicroPort Orthopedics Launches Improved Knee Replacement Product

MicroPort Orthopedics Launches Improved Knee Replacement Product

MicroPort Orthopedics, a US division of Shanghai’s medical device maker, MicroPort Scientific, launched the Evolution® NitrX™ Medial-Pivot Knee System, the latest version of its knee replacement product. The newest NitrX™ product features a...

Read more
I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

I-Mab Biopharma (“I-Mab”), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces on June 24, 2019, that the first patient has...

Read more
AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan

AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses...

Read more
Sinopharm Leads $20 Million Investment in Singapore’s Novena; Plans Joint $150 Million Healthcare Fund

Sinopharm Leads $20 Million Investment in Singapore’s Novena; Plans Joint $150 Million Healthcare Fund

Novena Global Lifecare, a Singapore company with 250 aesthetic clinics and sales outlets in southeast Asia, will receive an investment of up to $20 million from Sinopharm Capital and Cedarlake Capital. Founded in 2010, Novena is one of the...

Read more
Eli Lilly Unit Selects China’s Amoy Diagnostics’ Gene Products for Cancer Drug

Eli Lilly Unit Selects China’s Amoy Diagnostics’ Gene Products for Cancer Drug

China’s Amoy Diagnostics will partner with Loxo Oncology, a developer of targeted cancer drugs owned by Eli Lilly and Company, to supply it with accompanying reagents for genetic diagnosis during clinical trials of new drugs in Asia. The...

Read more
Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies

Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies

Target Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capitalize on the rapid internationalization of clinical trials between the US and China while...

Read more
Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region

Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region

Terns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic...

Read more
Eddingpharm In-Licenses Shionogi Thrombocytopenia Treatment

Eddingpharm In-Licenses Shionogi Thrombocytopenia Treatment

Eddingpharm in-licensed greater China rights to a treatment for thrombocytopenia, a side-effect of liver disease, from Shionogi of Japan. People with thrombocytopenia suffer from a low platelet count and are usually treated with via blood...

Read more
Wuhan’s XW Labs Gains US Orphan Drug Status for Narcolepsy Drug

Wuhan’s XW Labs Gains US Orphan Drug Status for Narcolepsy Drug

XW Labs of Wuhan received US Orphan Drug Designation status for its lead molecule, a clinical-stage treatment for narcolepsy. XW develops novel small molecule therapeutics for CNS disorders. Narcolepsy, an orphan disease that affects 1 in 2,000...

Read more
PwC says US companies are expected to spend 6% more on employee health care next year as drug prices rise

PwC says US companies are expected to spend 6% more on employee health care next year as drug prices rise

Employer medical costs are projected to rise by 6% next year, according to PwC. The rate of increase is a four-year high, due in part to rising drug prices. The jump is attributed to expensive specialty drugs that weren’t available a few years...

Read more
Six Biotech Companies with IPOs This Week

Six Biotech Companies with IPOs This Week

This week marked initial public offering (IPO) news from six biopharma companies. Here’s a look. BridgeBio Pharma. On June 17, BridgeBio set terms for its $240 million IPO. The company is based in Palo, Alto, Calif. and is expected to trade on...

Read more
Do NOT follow this link or you will be banned from the site!